Skip to main content
. Author manuscript; available in PMC: 2019 Feb 5.
Published in final edited form as: Neuroendocrinology. 2018 May 15;107(2):127–132. doi: 10.1159/000490059

Fig. 2.

Fig. 2.

Functional study of MKRN3 promoter variant. On the x-axis, “Empty” indicates pGL2 vector; “WT” indicates pGL2hMKRN3p_WT; “wT/delTCAG” indicates 50% pGL2hMKRN3p_WT + 50% pGL2hMKRN3p_delTCAG; and “delTCAG” indicates pGL2hMKRN3p_delTCAG. Values represent means ± standard deviations of 4 independent experiments, each performed in triplicate. The dose-dependent ANOVA test is represented by **** p < 0.0001 with Brown-Forsythe test p = 0.0089 and Bartlett’s test p < 0.0001. ** p < 0.01; *** p < 0.001; **** p < 0.0001. pGL2 was excluded from ANOVA analysis. ANOVA 750 ng: ns. ANOVA 1,500 ng: <0.0001; WT × WT/delTCAG: **; WT × delTCAG: ****. ANOVA 3,000 ng: 0.0002; WT × WT/delTCAG: **; WT × delTCAG: ***. ns, not significant.